ABVX | Abivax SA American Depositary Shares Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	7.77 - 8.14
52 Week Range	5.50 - 17.02
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	46,657
Average Volume	170,903
Shares Outstanding	63,371,869
Market Cap	512,044,702
Sector	Healthcare
Industry	Biotechnology
IPO Date	2023-10-20

Valuation
Profitability
Growth
Health
P/E Ratio	-2.24
Forward P/E Ratio	N/A
EPS	-3.60
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	62
Country	USA
Website	ABVX

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

*Chart delayed

Analyzing fundamentals for ABVX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see ABVX Fundamentals page.

Watching at ABVX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on ABVX Technicals page.